Aussie Try To Lower Drug Costs Ends Up Raising Most, Report Says
This article was originally published in PharmAsia News
Executive SummaryAustralia's attempt to lower the cost and obtain a better drug value under its health-insurance plan appears to have backfired, according to a report
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.